Welcome to our dedicated page for Barinthus Biotherapeutics plc. SEC filings (Ticker: BRNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Barinthus Biotherapeutics plc filings document material events, security structure, governance matters and clinical disclosures for a clinical-stage biopharmaceutical issuer organized in England and Wales. Recent Form 8-K reports describe American Depositary Shares listed under BRNS, with each ADS representing one ordinary share, along with capital-structure disclosures and emerging growth company status.
The company’s regulatory record also covers shareholder voting matters, material agreements, operating and financial results, clinical or regulatory updates related to its immunotherapy programs, and Nasdaq listing-compliance notices. These filings provide formal disclosure around the company’s ADR program, ordinary-share structure, board and governance matters, and public-company reporting obligations.
Q2-25 snapshot: Barinthus Biotherapeutics (BRNS) posted a net loss of $21.1 million (-24.6 % YoY) or -$0.52/sh; six-month loss widened to $40.8 million. Cash & equivalents fell to $86.3 million from $110.7 million at FY-24, but management still forecasts liquidity into early-2027.
Expense trends: R&D dropped 32 % YoY to $8.0 million as infectious-disease and oncology projects were shelved; however, G&A more than doubled to $15.4 million due mainly to an $8.0 million foreign-exchange loss and restructuring costs, lifting total operating spend 24 % to $23.3 million.
Balance sheet & risk: Current assets declined 20 % to $100.4 million; equity slid to $102.5 million. There is no debt, but cash burn averaged ~$17 million per quarter, and accumulated deficit reached $278.4 million.
Pipeline focus: Strategy now centres on immunology & inflammation. Lead SNAP-TI asset VTP-1000 (celiac disease) has completed dosing of two single-ascending-dose cohorts; topline safety/biomarker data expected early Q4-25. VTP-300 (HBV) will finish current Phase 2 trials while partnering options are explored; CEPI-funded MERS vaccine program is being exited.
Key watch-points: 1) VTP-1000 Phase 1 read-out, 2) ability to rein in G&A, 3) partnership progress for VTP-300, and 4) sustaining cash runway under current burn.